14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
MPLT vs ALMS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, MapLight Therapeutics, Inc. (MPLT) captures the overall head-to-head institutional edge over Alumis Inc. (ALMS) on higher Unified Composite conviction (50.4/100 HOLD vs. 43.3/100 HOLD) after splitting the core matrix 5–2 (led by Balance Sheet & Cash Flow, Options & Positioning), while ALMS wins 3–2 across the 6-pillar growth and valuation breakdown. MPLT trades at $6.94 (N/M Forward P/E, 0.0% operating margin) versus ALMS at $5.06 (N/M Forward P/E, -5744.5% operating margin).
Growth vs. Quality Trade-Off: MPLT earns the overall head-to-head edge with a stronger Unified Composite Score (50.4/100 HOLD vs. ALMS 43.3/100 HOLD) and 1.05β · 78% Vol risk profile, whereas ALMS leads top-line expansion (-37.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: MPLT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.7); meanwhile ALMS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MPLT vs ALMS. Trailing 12-month operating profitability (MPLT 0.0% vs ALMS -5744.5%) and valuation multiples (MPLT N/M vs ALMS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $793.4M market capitalization and -5744.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ MPLT vs ALMS Key Questions & Quantitative Answers
As of Nov 16, 2026, MapLight Therapeutics, Inc. (MPLT) captures the overall head-to-head institutional edge over Alumis Inc. (ALMS) on higher Unified Composite conviction (50.4/100 HOLD vs. 43.3/100 HOLD) after splitting the core matrix 5–2 (led by Balance Sheet & Cash Flow, Options & Positioning), while ALMS wins 3–2 across the 6-pillar growth and valuation breakdown. MPLT trades at $6.94 (N/M Forward P/E, 0.0% operating margin) versus ALMS at $5.06 (N/M Forward P/E, -5744.5% operating margin). Growth vs. Quality Trade-Off: MPLT earns the overall head-to-head edge with a stronger Unified Composite Score (50.4/100 HOLD vs. ALMS 43.3/100 HOLD) and 1.05β · 78% Vol risk profile, whereas ALMS leads top-line expansion (-37.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MPLT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.7); meanwhile ALMS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ALMS leads the Growth & Scale pillar: MPLT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ALMS at -37.7% YoY revenue growth and +0.0% YoY earnings growth on $7.4M TTM revenue (100.0% gross margin, -5744.5% operating margin). On trailing 12-month operating scale, MPLT generates N/A in USD-normalized revenue versus $7.4M for ALMS. In operating R&D and SG&A reinvestment, MPLT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ALMS.
ALMS screens cheaper on headline valuation multiples. MPLT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ALMS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 103.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MPLT (-111.5% ROE) versus ALMS (-93.7% ROE) capital efficiency.
In options market volatility and institutional positioning, MPLT carries 92.5% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.05β · 78% Vol realized risk). By comparison, ALMS carries 80.0% implied volatility (8th %ile, Compressed (<25th %ile)), a 4433.18x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.24β · 86% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.